200 related articles for article (PubMed ID: 17666487)
1. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.
Berthiaume M; Laplante M; Festuccia WT; Cianflone K; Turcotte LP; Joanisse DR; Olivecrona G; Thieringer R; Deshaies Y
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1045-52. PubMed ID: 17666487
[TBL] [Abstract][Full Text] [Related]
2. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Berthiaume M; Laplante M; Festuccia WT; Berger JP; Thieringer R; Deshaies Y
Int J Obes (Lond); 2009 May; 33(5):601-4. PubMed ID: 19223847
[TBL] [Abstract][Full Text] [Related]
3. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone facilitates lipid accumulation and mild feed restriction improves fatty acids oxidation in skeletal muscle of broiler chicks (Gallus gallus domesticus).
Wang X; Lin H; Song Z; Jiao H
Comp Biochem Physiol C Toxicol Pharmacol; 2010 May; 151(4):447-54. PubMed ID: 20138241
[TBL] [Abstract][Full Text] [Related]
5. Preliminary report: pharmacologic 11beta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet.
Berthiaume M; Laplante M; Festuccia WT; Berger JP; Thieringer R; Deshaies Y
Metabolism; 2010 Jan; 59(1):114-7. PubMed ID: 19766266
[TBL] [Abstract][Full Text] [Related]
6. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
[TBL] [Abstract][Full Text] [Related]
7. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
8. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Berthiaume M; Laplante M; Festuccia W; Gélinas Y; Poulin S; Lalonde J; Joanisse DR; Thieringer R; Deshaies Y
Endocrinology; 2007 May; 148(5):2391-7. PubMed ID: 17272400
[TBL] [Abstract][Full Text] [Related]
9. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
10. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
11. Masoprocol decreases serum triglyceride concentrations in rats with fructose-induced hypertriglyceridemia.
Scribner KA; Gadbois TM; Gowri M; Azhar S; Reaven GM
Metabolism; 2000 Sep; 49(9):1106-10. PubMed ID: 11016888
[TBL] [Abstract][Full Text] [Related]
12. Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity.
Liu Y; Sun WL; Sun Y; Hu G; Ding GX
Acta Pharmacol Sin; 2006 May; 27(5):588-96. PubMed ID: 16626514
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
14. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
15. Effects of gemfibrozil on triglyceride metabolism in Dahl salt-sensitive rats.
Donnelly R; Plato PA; Chang H; Reaven GM
J Pharmacol Exp Ther; 1994 Aug; 270(2):809-13. PubMed ID: 8071873
[TBL] [Abstract][Full Text] [Related]
16. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
[TBL] [Abstract][Full Text] [Related]
17. Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.
Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
J Lipid Res; 2011 May; 52(5):971-81. PubMed ID: 21364201
[TBL] [Abstract][Full Text] [Related]
18. Glycine normalizes hepatic triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats.
Yue JT; Mighiu PI; Naples M; Adeli K; Lam TK
Circ Res; 2012 May; 110(10):1345-54. PubMed ID: 22474253
[TBL] [Abstract][Full Text] [Related]
19. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
[TBL] [Abstract][Full Text] [Related]
20. Estimated liver weight is directly related to hepatic very low-density lipoprotein-triglyceride secretion rate in men.
Tsekouras YE; Magkos F; Kavouras SA; Panagiotakos DB; Sidossis LS
Eur J Clin Invest; 2008 Sep; 38(9):656-62. PubMed ID: 18837742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
